AssetMark Inc
TVRD

AssetMark Inc’s Tvardi Therapeutics TVRD Stock Holding History

AssetMark Inc’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1
Closed -$1K – 1566
2019
Q4 		$1K Hold
1
– – ﹤0.01% 1352
2019
Q3 		$1K Hold
1
– – ﹤0.01% 1274
2019
Q2 		$1K Hold
1
– – ﹤0.01% 1299
2019
Q1 		$1K Hold
1
– – ﹤0.01% 1298
2018
Q4 		$0 Buy
+1
New +$645 ﹤0.01% 1557

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AssetMark Inc's TVRD Position: Q1 2020 in Review

AssetMark Inc sold out of Tvardi Therapeutics (TVRD) in Q1 2020, closing a stake of 1 share — an estimated $1K sold.

AssetMark Inc first reported a position in TVRD in Q4 2018 and held it in 5 quarters. The position peaked at $1K in Q4 2019. 133 funds tracked by Wall St. Rank hold TVRD as of Q1 2020.

  • AssetMark Inc reported no remaining Tvardi Therapeutics position as of Q1 2020 after selling out during the quarter.
  • AssetMark Inc sold 1 Tvardi Therapeutics share in Q1 2020, an estimated $1K.
  • AssetMark Inc first reported a position in Tvardi Therapeutics in Q4 2018 and held it in 5 quarters.
  • AssetMark Inc's Tvardi Therapeutics position peaked at $1K in Q4 2019.
  • 133 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2020.

Based on AssetMark Inc's 13F filing for Q1 2020, filed 12 May 2020.